BlackRock Amends Vaxcyte Stake, Maintains Passive Investment
Ticker: PCVX · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a chunk of Vaxcyte, signaling institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Vaxcyte, Inc. (ticker not provided in filing, but company name is Vaxcyte, Inc.) Common Stock as of December 31, 2023. This filing, an amendment to a previous one, shows BlackRock's continued significant passive investment in the biotechnology company. For investors, this signals that a major institutional investor maintains confidence in Vaxcyte, Inc., which could be a positive indicator for the stock's stability and long-term prospects.
Why It Matters
This filing confirms BlackRock, a major institutional investor, continues to hold a significant stake in Vaxcyte, Inc., suggesting ongoing institutional confidence in the company's future.
Risk Assessment
Risk Level: low — This filing is routine and indicates a large, passive institutional investment, which generally reduces volatility rather than increasing risk.
Analyst Insight
Investors should view this as a confirmation of BlackRock's continued, passive institutional interest in Vaxcyte, Inc., which can be a positive signal for stability but doesn't indicate any immediate catalysts or changes in company direction.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Vaxcyte, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the date the SC 13G/A was filed
- 92243G108 (other) — the CUSIP number for Vaxcyte, Inc. Common Stock
Forward-Looking Statements
- BlackRock will likely maintain its passive investment in Vaxcyte, Inc. for the foreseeable future. (BlackRock Inc.) — high confidence, target: 2025-01-25
FAQ
What type of filing is this and who filed it?
This is an SC 13G/A filing, an amendment to a Schedule 13G, filed by BlackRock Inc.
Which company's stock is the subject of this filing?
The subject company is Vaxcyte, Inc., a company in the biological products industry (SIC 2836).
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required the filing of this statement was December 31, 2023.
What is the CUSIP number for the securities mentioned in the filing?
The CUSIP number for the Common Stock of Vaxcyte, Inc. is 92243G108.
What rule under the Securities Exchange Act of 1934 is this Schedule 13G filed under?
This Schedule 13G is filed under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Vaxcyte, Inc. (PCVX).